Johnson & Johnson Q2 Earnings Review: Why You Should Be Buying The Stock Today
Summarize this article with:
Edmund InghamInvesting Group LeaderFollow5ShareSavePlay(15min)Comment(1)SummaryJohnson & Johnson delivered a robust Q1, with revenues up nearly 10% YoY to $24.1bn and a raised full-year 2026 sales guidance above $100bn.JNJ's diversified portfolio—driven by double-digit growth in Innovative Medicines and strong growth in MedTech—positions it as "the cleanest growth story in healthcare."Most key products face minimal near-term patent risk, while new launches like icotrokinra, Rybrevant, and Inlexzo offer multibillion-dollar potential.Despite talc litigation risks, JNJ’s capital allocation, pipeline strength, and attractive forward multiples underpin a Strong Buy thesis.Haggerston BioHealth members get exclusive access to our real-world portfolio. See all our investments here » JHVEPhoto/iStock Editorial via Getty Images Investment Overview Johnson & Johnson (JNJ), the Pharmaceutical giant headquartered in New Brunswick, New Jersey, announced its Q1 earnings and business updates earlier today. At the time of writing, shares are trading broadly flatThis article was written byEdmund Ingham14.86K FollowersFollowEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis. Learn more.Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABBV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.